Prognosticating 2-Year Survival Rate of Breast Cancer Patients Through Plasma miRNA-21 and Other Associating Factors

References

• Yang Z, Liu Z. The emerging role of MicroRNAs in breast cancer. J Oncol. 2020;2020:9160905. doi:10.1155/2020/9160905
   PubMed Web of Science ®Google Scholar
• Isca C, Piacentini F, Mastrolia I, et al. Circulating and intracellular miRNAs as prognostic and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy: a review of the literature. Cancers. 2021;13(19):4894. doi:10.3390/cancers13194894
   PubMed Web of Science ®Google Scholar
• Zografos E, Zagouri F, Kalapanida D, Zakopoulou R. Prognostic role of microRNAs in breast cancer: a systematic review. Oncotarget. 2019;10(67):7156–7178. doi:10.18632/oncotarget.27327
   PubMedGoogle Scholar
• Sathipati SY, Ho S-Y, Araujo MTF. Identifying a miRNA signature for predicting the stage of breast cancer. Sci Rep. 2018;8(1):1–11. doi:10.1038/s41598-018-34604-3
   PubMed Web of Science ®Google Scholar
• Nam SE, Lim W, Jeong J, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat. 2019;177(3):669–678. doi:10.1007/s10549-019-05357-y
   PubMed Web of Science ®Google Scholar
• Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23(Suppl 2):S60–S64. doi:10.1038/modpathol.2010.33
   PubMed Web of Science ®Google Scholar
• Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Elizabeth A. Clinical medicine insights: oncology classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights. 2010;4:15–34. doi:10.4137/cmo.s4773
   Google Scholar
• Swellam M, Ramadan A, El-Hussieny EA, et al. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: comparative to conventional tumor markers. J Cell Biochem. 2019;120(8):12321–12330. doi:10.1002/jcb.28496
   PubMed Web of Science ®Google Scholar
• Pan F, Mao H, Deng L, Li G, Geng P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol. 2014;7(9):5622–5633.
   PubMed Web of Science ®Google Scholar
• Li J, Liu L, Feng Z, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020;27(4):621–630. doi:10.1007/s12282-020-01058-3
   PubMed Web of Science ®Google Scholar
• Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer. Oncol Lett. 2018;16(4):4679–4688. doi:10.3892/ol.2018.9160
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang H, Zhang M, Meng Q, Cai L, Zhang Q. Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncol Lett. 2017;14(6):7549–7556. doi:10.3892/ol.2017.7164
   PubMed Web of Science ®Google Scholar
• Shao Y, Sun X, He Y, Liu C, Liu H, Batra SK. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015;10(7):e0133830. doi:10.1371/journal.pone.0133830
   PubMed Web of Science ®Google Scholar
• Wu SG, He ZY, Zhou J, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88–93. doi:10.1016/j.breast.2013.11.003
   PubMed Web of Science ®Google Scholar
• Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 2013;24(5):1225–1231. doi:10.1093/annonc/mds604
   PubMed Web of Science ®Google Scholar
• Romadhon PZ, Prayoga AA, Bintoro SUY, et al. The association between plasma miRNA-21 levels with overall 1-year Survival rate of breast cancer patients at various stages. Acta Med Indones. 2021;53(4):432–441.
   PubMed Web of Science ®Google Scholar
• Diansyah MN, Prayogo AA, Sedana MP, et al. Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker. Turk j med sci. 2021;51(2):562–569. doi:10.3906/sag-2005-138
   PubMed Web of Science ®Google Scholar
• Savitri M, Bintoro U, Sedana M, et al. Circulating plasma miRNA-21 as a superior biomarker compared to CA 15-3: assessment in healthy age matched subjects and different stage of breast cancer patients. Indonesian Biomed J. 2020;12(2):157–164. doi:10.18585/inabj.v12i2.1142
   Web of Science ®Google Scholar
• Liu X, Cao M, Palomares M, et al. Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 2018;20(1):127. doi:10.1186/s13058-018-1059-y
   PubMed Web of Science ®Google Scholar
• Binabaj MM, Bahrami A, Khazaei M, et al. The prognostic value of small noncoding microRNA-21 expression in the survival of cancer patients: a meta-analysis. Crit Rev Eukaryot Gene Expr. 2020;30(3):207–221. doi:10.1615/CritRevEukaryotGeneExpr.2020028719
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Pan C, Ma F, Zhang S, Seagroves T. Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis. PLoS One. 2015;10(2):e0118647. doi:10.1371/journal.pone.0118647
   PubMed Web of Science ®Google Scholar
• Jinling W, Sijing S, Jie Z, Guinian W. Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2017;45(6):1–6. doi:10.1080/21691401.2016.1216856
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhou X, Ji J, et al. High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Markers. 2015;30(4):e347–e358. doi:10.5301/jbm.5000160
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13. doi:10.3121/cmr.2009.825
   PubMedGoogle Scholar
• Van Asten K, Slembrouck L, Olbrecht S, et al. Prognostic value of the progesterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer. Oncologist. 2019;24(2):165–171. doi:10.1634/theoncologist.2018-0176
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Hill DA, Barry M, Wiggins C, et al. Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat. 2017;166(3):855–864. doi:10.1007/s10549-017-4439-6
   PubMed Web of Science ®Google Scholar
• Gaglia P, Caldarola B, Bussone R, et al. Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis. Eur J Cancer Clin Oncol. 1988;24(7):1151–1155. doi:10.1016/0277-5379(88)90121-6
   PubMedGoogle Scholar
• Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002;86(8):1217–1222. doi:10.1038/sj.bjc.6600248
   PubMed Web of Science ®Google Scholar
• Laessig D, Nagel D, Heinemann V, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27(4a):1963–1968.
   PubMed Web of Science ®Google Scholar
• Park BW, Oh JW, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19(4):675–681. doi:10.1093/annonc/mdm538
   PubMed Web of Science ®Google Scholar
• Li X, Dai D, Chen B, et al. Prognostic values of preoperative serum CEA and CA125 levels and nomograms for young breast cancer patients. Onco Targets Ther. 2019;12:8789–8800. doi:10.2147/ott.s221335
   PubMed Web of Science ®Google Scholar